People on the move in March 2007.
Washington, DC (Mar. 16)—Kevin Sharer, CEO and president of Amgen (Thousand Oaks, CA, www.amgen.com~), was re-elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA, www.phrma.org~). In addition, Richard Clark, CEO and president of Merck and Co., Inc. (Whitehouse Station, www.merck.com~) was elected chairman-elect of PhRMA's board. David Brennan, CEO of AstraZeneca (London, www.astrazeneca.com~) was elected treasurer of PhRMA's board. Pfizer, Inc. (New York, NY, www.pfizer.com~) Chairman and CEO Jeffrey Kindler was made a member of PhRMA's board of directors.
Albany, NY (Mar. 14)—Albany Moleculare Research, Inc. (AMRI, www.albanymolecular.com~) named Jonathan D. Evans vice-president of pharmaceutical development and manufacturing. He will be responsible for AMRI's chemical development, small-scale CGMP manufacturing, quality control and assurance, and large-scale manufacturing.
Rockville, MD (Mar. 14)—James M. Robinson was appointed vice-president of technical and quality operations for Novavax, Inc. (www.novavax.com~). Robinson joins Novavax from Sanofi Pasteur, where he was responsible for the company's sterile manufacturing operations.
Vancouver, BC, Canada (Mar. 13)—Robert DuFresne was appointed president and chief executive officer of Pacgen Biopharmaceuticals Corporation (www.pacgenbiopharm.com~). DuFresne joins Pacgen from Zelos Therapeutics, Inc., where he was chief executive officer. He was also president and CEO of ConjuChem Inc.
San Carlos, CA (Mar. 12)—Thomas L. Feldman was appointed president, chief executive officer, and a member of the board of directors of POINT Biomedical Corp. (www.pointbio.com~). Feldman was previously president and chief business officer at COTHERIX, Inc.
Evry, France (Mar. 12)—BioSystems International (www.biosys-intl.com~) appointed Jean Pierre Tirouflet CEO. He formerly was chairman and CEO of the specialty-chemicals company Rhodia.
Gurgaon, India (Mar. 11)—Ranbaxy Laboratories Limited (www.ranbaxy.com~) appointed Himadri Sen president of research and development for generics and NDDS.
Foster City, CA (Mar. 9)—Norbert W. Bischofberger, PhD, was appointed executive vice-president of research and development of Gilead Sciences, Inc. (www.gilead.com~). In addition, John F. Milligan, PhD, was promoted to chief operating officer. Bischofberger and Milligan both joined the company in 1990.
San Francisco, CA (Mar. 8)—Inventech promoted Ian Fitzpatrick to manager of manufacturing innovation in North America. Fitzpatrick previously held a project management role at Inventech's Australian offices.
Woodcliff Lake, NJ (Mar. 7)—Par Pharmaceutical Companies, Inc. (www.parpharm.com~) promoted Paul V. Campanelli to president of its generics division. Campanelli joined the company in 2001 after holding positions at Dr. Reddy's Laboratories, Inc., and Reddy-Cheminor, Inc.
Vancouver, BC, Canada (Mar. 7)—Victor Diaz was appointed senior vice-president of global manufacturing and supply chain management for Angiotech Pharmaceuticals, Inc. (www.angiotech.com~). Diaz previously served as vice-president of global operations at Teleflex Medical.
Mississauga, ON, Canada (Mar. 7)—Vasogen Inc. (www.vasogen.com~) appointed board member Terrance H. Gregg president and chief executive officer. Gregg, formerly the president and chief operating officer of MiniMed Inc., succeeds David G. Elsley.
Cambridge, MA (Mar. 6)—ImmunoGen, Inc. (www.immunogen.com~) announced the departure of executive vice-president of science and technology Walter Blattler, PhD. Until a replacement is found, Blattler's responsibilities will be assumed by John Lambert, PhD, senior vice-president of pharmaceutical development; Pauline Ryan, senior vice-president of corporate development and operations; and Mitchel Sayare, PhD, chairman and CEO of ImmunoGen.
Cambridge, MA (Mar. 5)—David A. Broecker was promoted to president and chief executive officer of Alkermes, Inc. (www.alkermes.com~). Broecker has served as Alkermes's president since 2001 and was appointed chief operating officer in 2002.
Cranbury, NJ (Mar. 5)—John F. Crowley returned to his position as president and chief executive officer of Amicus Therapeutics (www.amicustherapeutics.com~). Crowley took a leave of absence in order to complete a six-month tour of duty with the US Navy.
San Francisco, CA (Mar. 1)—Bridge Pharmaceuticals (www.bridgecro.com~) appointed James Carignan vice-president of quality assurance and regulatory compliance for its Beijing operations. Carignan formerly was responsible for directing the quality-assurance program at Novartis.